MBMercedes J. Burnside

Mercedes J. Burnside

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mercedes J. Burnside has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Benjamin J. Wheeler

    Department of Women’s and Children’s Health, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand

    2 shared publications
  • Craig A. Jefferies

    Department of Pediatric Endocrinology, Starship Children's Health, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand

    2 shared publications
  • Hamish Crocket

    Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand

    2 shared publications
  • Jonathan A. Williman

    Department of Population Health, University of Otago, Christchurch, Christchurch, New Zealand

    2 shared publications
  • Martin Isaac de Bock

    Department of Paediatrics, University of Otago, Christchurch, New Zealand

    2 shared publications
  • Ryan G. Paul

    Te Huataki Waiora School of Health, Sport & Human Performance, University of Waikato, Hamilton, New Zealand

    2 shared publications

Latest Publications

  • Open Access

    Continuous subcutaneous octreotide infusion in congenital hyperinsulinism: practical application and insights in infancy and early childhood

    by Mercedes J. Burnside, Adam Stafford-Bell, Rachel Romans, Matthew Moller, Catherine S. Choong, Mary B. Abraham

    Purpose: Octreotide is second-line treatment for patients with congenital hyperinsulinism (CHI) unresponsive to diazoxide. Short-acting octreotide is administered via subcutaneous (SC) injection or continuous infusion using a pump, but limited data exist on pump therapy. We present two cases of CHI managed with an octreotide infusion via pump with or without concurrent continuous glucose monitoring (CGM), providing practical guidance. Case presentation: Octreotide 500mcg/1ml ampoule was used. The starting dose was 5mcg/kg/day, with titration to optimize glycaemia, and delivered as a continuous basal rate using a pump. CGM was used by Patient 2. Patient 1: CHI due to a paternal ABCC8 mutation was detected at 16 weeks of age, with diffuse uptake on 18F-DOPA PET. Unresponsive to diazoxide, SC octreotide injections commenced, transitioning to an infusion (13mcg/kg/day) with good response, and complete cessation of therapy at four years. Patient 2: Neonate with CHI due to Beckwith Wiedemann Syndrome developed side-effects from diazoxide and was commenced on SC octreotide injections. Effective at 30mcg/kg/day, he transitioned to an infusion at 4.5 months followed by long-acting octreotide at 12 months. Both patients tolerated the infusion with no adverse effects. Conclusion: This report highlights the practical use of octreotide infusion via pump. When combined with CGM, it allows for tailored dosing to meet individual needs while enhancing patient convenience.


  • Extended Use of an Open-Source Automated Insulin Delivery System in Children and Adults with Type 1 Diabetes: The 24-Week Continuation Phase Following the CREATE Randomized Controlled Trial

    by Mercedes J. Burnside, Dana M. Lewis, Hamish R. Crocket, Renee A. Meier, Jonathan A. Williman, Olivia J. Sanders, Craig A. Jefferies, Ann M. Faherty, Ryan G. Paul, Claire S. Lever, et al.

    Aim: To assess long-term efficacy and safety of open-source automated insulin delivery (AID) in children and adults (7–70 years) with type 1 diabetes. Methods: Both arms of a 24-week randomized controlled trial comparing open-source AID (OpenAPS algorithm within a modified version of AndroidAPS, preproduction DANA-i™ insulin pump, Dexcom G6 continuous glucose monitor) with sensor-augmented pump therapy (SAPT), entered a 24-week continuation phase where the SAPT arm (termed SAPT-AID) crossed over to join the open-source AID arm (termed AID-AID). Most participants (69/94) used a preproduction YpsoPump ® insulin pump during the continuation phase. Analyses incorporated all 52 weeks of data, and combined between-group and within-subject differences to calculate an overall “treatment effect” of AID versus SAPT. Results: Mean time in range (TIR; 3.9–10 mmol/L [70–180 mg/dL]) was 12.2% higher with AID than SAPT (95% confidence interval [CI] 10.4 to 14.1; P < 0.001). TIR was 56.9% (95% CI 54.2 to 59.6) with SAPT and 69.1% (95% CI 67.1 to 71.1) with AID. The treatment effect did not differ by age ( P = 0.39) or insulin pump type ( P = 0.37). HbA1c was 5.1 mmol/mol lower [0.5%] with AID (95% CI −6.6 to −3.6; P < 0.001). There were no episodes of diabetic ketoacidosis or severe hypoglycemia with either treatment over the 48 weeks. Six participants (all in SAPT-AID) withdrew: three with hardware issues, two preferred SAPT, and one with infusion-site skin irritation. Conclusion: Further evaluation of the community derived automated insulin delivery (CREATE) trial to 48 weeks confirms that open-source AID is efficacious and safe with different insulin pumps, and demonstrates sustained glycemic improvements without additional safety concerns.


  • Open Access

    Interviews with Indigenous Māori with type 1 diabetes using open-source automated insulin delivery in the CREATE randomised trial

    by Mercedes Burnside, Tracy Haitana, Hamish Crocket, Dana Lewis, Renee Meier, Olivia Sanders, Craig Jefferies, Ann Faherty, Ryan Paul, Claire Lever, et al.

    Purpose: Open-source automated insulin delivery (AID) is used by thousands of people with type 1 diabetes (T1D), but has unknown generalisability to marginalised ethnic groups. This study explored experiences of Indigenous Māori participants in the CREATE trial with use of an open-source AID system to identify enablers/barriers to health equity. Methods: The CREATE randomised trial compared open-source AID (OpenAPS algorithm on an Android phone with a Bluetooth-connected pump) to sensor-augmented pump therapy. Kaupapa Māori Research methodology was used in this sub-study. Ten semi-structured interviews with Māori participants (5 children, 5 adults) and whānau (extended family) were completed. Interviews were recorded and transcribed, and data were analysed thematically. NVivo was used for descriptive and pattern coding. Results: Enablers/barriers to equity aligned with four themes: access (to diabetes technologies), training/support, operation (of open-source AID), and outcomes. Participants described a sense of empowerment, and improved quality of life, wellbeing, and glycaemia. Parents felt reassured by the system’s ability to control glucose, and children were granted greater independence. Participants were able to use the open-source AID system with ease to suit whānau needs, and technical problems were manageable with healthcare professional support. All participants identified structures in the health system precluding equitable utilisation of diabetes technologies for Māori. Conclusion: Māori experienced open-source AID positively, and aspired to use this therapy; however, structural and socio-economic barriers to equity were identified. This research proposes strength-based solutions which should be considered in the redesign of diabetes services to improve health outcomes for Māori with T1D. Trial Registration: The CREATE trial, encompassing this qualitative sub-study, was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12620000034932p) on the 20th January 2020.


  • Open Access

    Inequity in access to continuous glucose monitoring and health outcomes in paediatric diabetes, a case for national continuous glucose monitoring funding: a cross-sectional population study of children with type 1 diabetes in New Zealand

    by Mercedes J. Burnside, Jonathan A. Williman, Hannah M. Davies, Craig A. Jefferies, Ryan G. Paul, Benjamin J. Wheeler, Esko J. Wiltshire, Yvonne C. Anderson, Martin I. de Bock


  • Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic review

    by N. A. M. Asarani, A. N. Reynolds, M. Elbalshy, M. Burnside, M. de Bock, D. M. Lewis, B. J. Wheeler

    The do-it-yourself artificial pancreas system (DIYAPS) is a patient-driven initiative with the potential to revolutionise diabetes management, automating insulin delivery with existing pumps and CGM combined with open-source algorithms. Given the considerable interest in this topic within the diabetes community, we have conducted a systematic review of DIYAPS efficacy, safety, and user experience. Following recognised procedures and reporting standards, we identified 10 eligible publications of 730 participants within the peer-reviewed literature. Overall, studies reported improvements in time in range, HbA1c (glycated haemoglobin), reduced hypoglycaemia, and improved quality of life with DIYAPS use. While results were positive, the identified studies were small, and the majority were observational and at high risk of bias. Further research including well-designed randomised trials comparing DIYAPS with appropriate comparators is recommended.


  • Do-It-Yourself Automated Insulin Delivery: A Leading Example of the Democratization of Medicine

    by Mercedes Burnside, Hamish Crocket, Michael Mayo, John Pickering, Adrian Tappe, Martin de Bock

    Digital innovations have led to an explosion of data in healthcare, driving processes of democratization and foreshadowing the end of the paternalistic era of medicine and the inception of a new epoch characterized by patient-centered care. We illustrate that the “do it yourself” (DIY) automated insulin delivery (AID) innovation of diabetes is a leading example of democratization of medicine as evidenced by its application to the three pillars of democratization in healthcare (intelligent computing; sharing of information; and privacy, security, and safety) outlined by Stanford but also within a broader context of democratization. The heuristic algorithms integral to DIY AID have been developed and refined by human intelligence and demonstrate intelligent computing. We deliver examples of research in artificial pancreas technology which actively pursues the use of machine learning representative of artificial intelligence (AI) and also explore alternate approaches to AI within the DIY AID example. Sharing of information symbolizes the core philosophy behind the success of the DIY AID evolution. We examine data sharing for algorithm development and refinement, for sharing of the open-source algorithm codes online, for peer to peer support, and sharing with medical and scientific communities. Do it yourself AID systems have no regulatory approval raising safety concerns as well as medico-legal and ethical implications for healthcare professionals. Other privacy and security factors are also discussed. Democratization of healthcare promises better health access for all and we recognize the limitations of DIY AID as it exists presently, however, we believe it has great potential.